Cryo-Cell Announces Partnership with National Institutes of Health
News Nov 19, 2008
Cryo-Cell International Inc. and the National Institutes of Health (NIH) Clinical Center have announced a research partnership to conduct an exploratory study to determine the homing capabilities of Cryo-Cell's proprietary Endometrial Menstrual Stem Cells (MenSCs) in a breast cancer model.
The NIH Clinical Center research team, led by Dr. Joseph Frank, will label the MenSCs with iron oxide nanoparticles, which will make it possible to track the distribution of the MenSCs in the body using magnetic resonance imaging (MRI). The ability to use MRI to monitor the migration of the MenSCs may provide the basis for determining the future utility of MenSCs in the treatment of disease.
"We know that the MenSCs are capable of differentiating into different cell types, and that they have the ability to divide rapidly," said Julie Allickson, Ph.D., Vice President of Laboratory Operations and Research and Development at Cryo-Cell. "The study may provide the basis for determining future use of these cells to treat diseases."
Clinical non-invasive imaging techniques that allow for long term tracking of stem cells in vivo do not currently exist. The Experimental Neuroimaging Section of Radiology and Imaging Sciences at the NIH Clinical Center has developed techniques to label stem cells with the FDA approved agent, ferumoxides (FE), which is commonly used as a contrast agent with magnetic resonance (MR) imaging. By using FE, researchers in the Experimental Neuroimaging Section of the LDRR are able to track the temporal and spatial migration by MRI.
Dr. Frank and his colleagues in the Experimental Neuroimaging Section of Radiology and Imaging Sciences will evaluate the labeling efficiency of MenSCs to determine if there is any alteration in differentiation potential, proliferative capacity, metabolic alterations, apoptosis rate and/or an increase in iron content of the tracked cells compared to unlabeled cells.
Following the in vitro evaluation of FEPro (ferumoxides complexed to protamine sulfate) labeled endometrial cell function, if the MenSCs are not altered by FEPro labeling, a series of in vivo MRI studies will be conducted in rodent tumor models to determine if the magnetically labeled cells will migrate to and integrate into the tumor.
Further studies may be added that will explore the therapeutic uses of MenSCs at the molecular level, as gene therapy or delivery vehicles for nanotherapeutic chemotherapeutic agents to treat cancer if the present research supports such studies.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE